Regulatory FDA points to liver injury with Amgen’s Tavneos PharmaphorumThe FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.RegulatoryImmunology & InflammationRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug. RegulatoryImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly outlays $7.8bn to acquire sleep drug biotech CentessaNext: Telomir seeks FDA approval for Telomir-1 to treat breast cancer Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
